MA43459A1 - Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers - Google Patents
Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancersInfo
- Publication number
- MA43459A1 MA43459A1 MA43459A MA43459A MA43459A1 MA 43459 A1 MA43459 A1 MA 43459A1 MA 43459 A MA43459 A MA 43459A MA 43459 A MA43459 A MA 43459A MA 43459 A1 MA43459 A1 MA 43459A1
- Authority
- MA
- Morocco
- Prior art keywords
- peptides
- cells
- carriers
- present
- various cancers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Abstract
La présente invention concerne des peptides, des protéines, des acides nucléiques et des cellules pour utilisation dans des procédés immunothérapeutiques. La présente invention concerne, en particulier, l'immunothérapie du cancer. La présente invention concerne, en outre, des épitopes peptidiques des lymphocytes t associés à une tumeur, seuls ou en combinaison avec d'autres peptides associés à une tumeur, qui peuvent, par exemple, servir de principes pharmaceutiques actifs pour des compositions vaccinales qui stimulent les réponses immunitaires antitumorales, ou pour stimuler des lymphocytes t ex vivo et les transférer aux patients. Des peptides liés aux molécules du complexe majeur d'histocompatibilité (cmh), ou des peptides en tant que tels, peuvent également être des cibles d'anticorps, de récepteurs des lymphocytes t solubles et d'autres molécules de liaison.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1515321.6A GB201515321D0 (en) | 2015-08-28 | 2015-08-28 | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| PCT/EP2016/070146 WO2017036936A1 (fr) | 2015-08-28 | 2016-08-26 | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitement immunothérapeutique de divers cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43459A1 true MA43459A1 (fr) | 2019-08-30 |
Family
ID=54326487
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43460A MA43460A1 (fr) | 2015-08-28 | 2016-08-26 | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers |
| MA045073A MA45073A (fr) | 2015-08-28 | 2016-08-26 | Nouveaux peptides, combinaison de peptides et d'échafaudages destinés à être utilisés dans le traitement immunothérapeutique de divers cancers |
| MA43458A MA43458A1 (fr) | 2015-08-28 | 2016-08-26 | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers |
| MA43461A MA43461B1 (fr) | 2015-08-28 | 2016-08-26 | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers |
| MA43457A MA43457A1 (fr) | 2015-08-28 | 2016-08-26 | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers |
| MA042694A MA42694A (fr) | 2015-08-28 | 2016-08-26 | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitement immunothérapeutique de divers cancers |
| MA43459A MA43459A1 (fr) | 2015-08-28 | 2016-08-26 | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers |
Family Applications Before (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43460A MA43460A1 (fr) | 2015-08-28 | 2016-08-26 | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers |
| MA045073A MA45073A (fr) | 2015-08-28 | 2016-08-26 | Nouveaux peptides, combinaison de peptides et d'échafaudages destinés à être utilisés dans le traitement immunothérapeutique de divers cancers |
| MA43458A MA43458A1 (fr) | 2015-08-28 | 2016-08-26 | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers |
| MA43461A MA43461B1 (fr) | 2015-08-28 | 2016-08-26 | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers |
| MA43457A MA43457A1 (fr) | 2015-08-28 | 2016-08-26 | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers |
| MA042694A MA42694A (fr) | 2015-08-28 | 2016-08-26 | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitement immunothérapeutique de divers cancers |
Country Status (18)
| Country | Link |
|---|---|
| US (7) | US10576132B2 (fr) |
| EP (2) | EP3461494A1 (fr) |
| JP (2) | JP6970974B2 (fr) |
| KR (3) | KR102308798B1 (fr) |
| CN (1) | CN107921111B (fr) |
| AU (3) | AU2016313684B2 (fr) |
| BR (1) | BR112018003460A2 (fr) |
| CA (2) | CA3072922A1 (fr) |
| CR (6) | CR20200493A (fr) |
| EA (2) | EA201891874A3 (fr) |
| GB (1) | GB201515321D0 (fr) |
| MA (7) | MA43460A1 (fr) |
| MX (1) | MX2018002480A (fr) |
| PE (2) | PE20181164A1 (fr) |
| SG (3) | SG10202001830PA (fr) |
| TW (15) | TWI722662B (fr) |
| UA (1) | UA124577C2 (fr) |
| WO (1) | WO2017036936A1 (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201507030D0 (en) * | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201515321D0 (en) * | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| JP7114477B2 (ja) | 2015-12-16 | 2022-08-08 | グリットストーン バイオ インコーポレイテッド | 新生抗原の特定、製造、および使用 |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| EP4317432A3 (fr) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | Récepteurs de lymphocytes t à appariement amélioré |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| CN108250286B (zh) * | 2016-12-28 | 2021-06-08 | 香雪生命科学技术(广东)有限公司 | 源自于pasd1的肿瘤抗原短肽 |
| TW201841937A (zh) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | 用於白血病和其他癌症免疫治療的新穎肽和肽組合物 |
| MA49123A (fr) | 2017-04-10 | 2020-03-25 | Immatics Biotechnologies Gmbh | Peptides et combinaison de peptides à utiliser en immunothérapie contre les leucémies et d'autres cancers |
| DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| US20190016802A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| PL3688155T3 (pl) * | 2017-09-28 | 2023-09-11 | Immpact-Bio Ltd. | Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar) |
| CN111465989B (zh) | 2017-10-10 | 2024-06-25 | 磨石生物公司 | 使用热点进行的新抗原鉴别 |
| AU2018373154B2 (en) | 2017-11-22 | 2025-08-07 | Seattle Project Corp. | Reducing junction epitope presentation for neoantigens |
| DE102018107224A1 (de) * | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| TW202016131A (zh) * | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
| CN109467596B (zh) * | 2018-11-12 | 2021-11-09 | 湖北省农业科学院畜牧兽医研究所 | 转录因子sp1在调控猪rtl1基因表达中的应用 |
| CN109738929B (zh) * | 2018-12-03 | 2022-10-21 | 中国辐射防护研究院 | 一种基于居民食物最大消费量的剂量估算方法及系统 |
| TWI858016B (zh) * | 2019-02-18 | 2024-10-11 | 日商肽夢想股份有限公司 | 血球凝集素結合肽 |
| WO2020230792A1 (fr) * | 2019-05-13 | 2020-11-19 | 伊東 恭悟 | Procédé pour déterminer l'éligibilité de patients atteints d'un cancer pour une thérapie vaccinale peptidique |
| CN110123453B (zh) * | 2019-05-31 | 2021-07-23 | 东北大学 | 一种基于无标记增强现实的手术导航系统 |
| CA3173664A1 (fr) * | 2020-04-14 | 2021-10-21 | Claude Perreault | Nouveaux antigenes specifiques a une tumeur pour la la leucemie lymphoblastique aigue (all) |
| CN111910000B (zh) * | 2020-07-02 | 2022-07-01 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 一种预测鼻咽癌预后的肿瘤微环境成分标志物组合及系统 |
| US20240207406A1 (en) * | 2021-04-19 | 2024-06-27 | Board Of Regents, The University Of Texas System | Methods and compositions comprising mhc class i peptides |
| JP2024526836A (ja) * | 2021-07-19 | 2024-07-19 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Fanci、rad51、およびpbk抗原を標的とするペプチドおよび操作されたt細胞受容体ならびに使用の方法 |
| CN115607573B (zh) * | 2022-12-16 | 2023-05-23 | 北京大学第三医院(北京大学第三临床医学院) | 一种用于调节杀伤性t细胞活性的方法、药物及其应用 |
| IL330155A (en) * | 2023-07-13 | 2026-08-01 | Ltz Therapeutics Inc | Multispecific antibodies and their uses |
| CN118834328B (zh) * | 2024-07-02 | 2025-09-16 | 江苏海洋大学 | 金属蛋白酶9抗原决定基印迹纳米颗粒的制备方法及应用 |
| CN120183512B (zh) * | 2025-05-23 | 2025-08-12 | 浙江省肿瘤医院 | 基于转录组测序构建的用于诊断早期宫颈癌淋巴结转移的方法、模型 |
| CN120908452B (zh) * | 2025-09-28 | 2025-12-02 | 吉林大学 | 一种用于卵巢癌初步筛查的试剂盒及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2766395A (en) * | 1995-06-05 | 1996-12-24 | Human Genome Sciences, Inc. | Human g-protein receptor hgber32 |
| CA2323632A1 (fr) * | 1998-03-13 | 1999-09-16 | Epimmune Inc. | Peptides de liaison de hla et leurs applications |
| US7342108B2 (en) * | 1998-06-25 | 2008-03-11 | The General Hospital Corporation | De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof |
| JP4315301B2 (ja) | 1998-10-30 | 2009-08-19 | 独立行政法人科学技術振興機構 | ヒトH37タンパク質と、このタンパク質をコードする cDNA |
| US6680197B2 (en) * | 1998-12-28 | 2004-01-20 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| CA2311201A1 (fr) * | 1999-08-05 | 2001-02-05 | Genset S.A. | Sequences marqueurs exprimees et proteines humaines codees |
| US20040002068A1 (en) * | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| GB0119473D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca | Compounds |
| WO2003016523A1 (fr) * | 2001-08-21 | 2003-02-27 | Millennium Pharmaceuticals, Inc. | Crible pour inhibiteurs de cdc7 |
| US7193069B2 (en) * | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| DE10316701A1 (de) | 2003-04-09 | 2004-11-04 | Hinzmann, Bernd, Dr. | Humane Nukleinsäuresequenzen aus Bronchialkarzinomen |
| EP1622934A2 (fr) * | 2003-05-05 | 2006-02-08 | Pharmacia Italia S.p.A. | Formes tronquees de la dbf4 humaine, complexes avec leurs partenaires d'interaction et procedes destines a l'identification de leurs inhibiteurs |
| EP1892306A3 (fr) | 2003-10-06 | 2008-06-11 | Bayer HealthCare AG | Méthode et trousses pour évaluer un cancer |
| JP4721903B2 (ja) * | 2004-01-29 | 2011-07-13 | 大日本住友製薬株式会社 | 新規腫瘍抗原蛋白質及びその利用 |
| US8536313B2 (en) * | 2007-07-10 | 2013-09-17 | Shionogi & Co., Ltd. | Monoclonal antibody having neutralizing activity against MMP13 |
| HUE025636T2 (en) * | 2007-07-27 | 2016-04-28 | Immatics Biotechnologies Gmbh | Novel immunogenic epitopes for immunotherapy |
| RS54204B1 (sr) * | 2007-07-27 | 2015-12-31 | Immatics Biotechnologies Gmbh | Nova imunoterapija protiv tumora mozga |
| WO2009051769A1 (fr) * | 2007-10-17 | 2009-04-23 | The Board Of Trustees Of The Leland Stanford Junior University | Procédé et composition pour la cristallisation de récepteurs couplés aux glycoprotéines |
| CN102165688A (zh) | 2008-03-31 | 2011-08-24 | 新加坡科技研究局 | 高效率线性发射器 |
| TW201000115A (en) * | 2008-06-11 | 2010-01-01 | Oncotherapy Science Inc | IQGAP3 epitope peptides and vaccines containing the same |
| ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
| WO2010037395A2 (fr) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer |
| ITBO20090075A1 (it) * | 2009-02-13 | 2010-08-14 | Magneti Marelli Spa | Macchina elettrica con singolo statore e due rotori tra loro indipendenti e veicolo stradale provvisto di tale macchina elettrica |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| WO2012048291A2 (fr) * | 2010-10-08 | 2012-04-12 | Proteapex Therapeutics Llc | Compositions et procédés pour l'inhibition d'interactions de substrat de mmp:mmp |
| SG191977A1 (en) * | 2011-02-01 | 2013-08-30 | Genmab As | Human antibodies and antibody-drug conjugates against cd74 |
| US10226238B2 (en) | 2011-09-12 | 2019-03-12 | Creatics Llc | Non-invasive methods of detecting target molecules |
| WO2013070603A1 (fr) | 2011-11-11 | 2013-05-16 | Cedars-Sinai Medical Center | Compositions et méthodes de traitement de maladies rénales |
| WO2013151664A1 (fr) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Polynucléotides modifiés pour la production de protéines |
| US10501512B2 (en) * | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| CA2880331A1 (fr) * | 2012-08-15 | 2014-02-20 | Universite De Montreal | Procede pour l'identification de nouveaux antigenes d'histocompatibilite mineure |
| US9879065B2 (en) * | 2012-09-14 | 2018-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing MHC class II-restricted MAGE-A3 |
| WO2014160275A2 (fr) | 2013-03-14 | 2014-10-02 | Battell Memorial Institute | Biomarqueurs pour la fibrose hépatique |
| TWI714869B (zh) | 2013-08-05 | 2021-01-01 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物 |
| WO2015092710A1 (fr) * | 2013-12-19 | 2015-06-25 | Glaxosmithkline Biologicals, S.A. | Administration simultanée controlatérale de vaccins |
| GB201515321D0 (en) * | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| AU2017254477A1 (en) * | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
| TW202016131A (zh) | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
| US11945850B2 (en) | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
-
2015
- 2015-08-28 GB GBGB1515321.6A patent/GB201515321D0/en not_active Ceased
-
2016
- 2016-08-26 MA MA43460A patent/MA43460A1/fr unknown
- 2016-08-26 TW TW108141497A patent/TWI722662B/zh not_active IP Right Cessation
- 2016-08-26 TW TW109122012A patent/TWI782290B/zh not_active IP Right Cessation
- 2016-08-26 CN CN201680050119.7A patent/CN107921111B/zh not_active Expired - Fee Related
- 2016-08-26 TW TW108141498A patent/TWI722663B/zh not_active IP Right Cessation
- 2016-08-26 TW TW108141496A patent/TWI722661B/zh not_active IP Right Cessation
- 2016-08-26 MA MA045073A patent/MA45073A/fr unknown
- 2016-08-26 BR BR112018003460-6A patent/BR112018003460A2/pt not_active Application Discontinuation
- 2016-08-26 AU AU2016313684A patent/AU2016313684B2/en not_active Ceased
- 2016-08-26 SG SG10202001830PA patent/SG10202001830PA/en unknown
- 2016-08-26 PE PE2018000318A patent/PE20181164A1/es unknown
- 2016-08-26 KR KR1020187023153A patent/KR102308798B1/ko not_active Expired - Fee Related
- 2016-08-26 CR CR20200493A patent/CR20200493A/es unknown
- 2016-08-26 EP EP18201208.8A patent/EP3461494A1/fr not_active Withdrawn
- 2016-08-26 KR KR1020217031080A patent/KR102515909B1/ko active Active
- 2016-08-26 KR KR1020187007555A patent/KR20180038550A/ko not_active Ceased
- 2016-08-26 MX MX2018002480A patent/MX2018002480A/es unknown
- 2016-08-26 CR CR20200495A patent/CR20200495A/es unknown
- 2016-08-26 TW TW108141489A patent/TWI722655B/zh not_active IP Right Cessation
- 2016-08-26 EP EP16762752.0A patent/EP3341014A1/fr not_active Withdrawn
- 2016-08-26 TW TW108141494A patent/TWI722659B/zh not_active IP Right Cessation
- 2016-08-26 CR CR20200494A patent/CR20200494A/es unknown
- 2016-08-26 TW TW108141490A patent/TWI722656B/zh not_active IP Right Cessation
- 2016-08-26 CR CR20180423A patent/CR20180423A/es unknown
- 2016-08-26 SG SG10201807588TA patent/SG10201807588TA/en unknown
- 2016-08-26 TW TW108141488A patent/TWI722654B/zh not_active IP Right Cessation
- 2016-08-26 TW TW108141491A patent/TWI722657B/zh not_active IP Right Cessation
- 2016-08-26 CR CR20180174A patent/CR20180174A/es unknown
- 2016-08-26 TW TW108141499A patent/TWI722664B/zh not_active IP Right Cessation
- 2016-08-26 EA EA201891874A patent/EA201891874A3/ru unknown
- 2016-08-26 TW TW108141487A patent/TWI722653B/zh not_active IP Right Cessation
- 2016-08-26 JP JP2018511114A patent/JP6970974B2/ja not_active Expired - Fee Related
- 2016-08-26 TW TW108141495A patent/TWI722660B/zh not_active IP Right Cessation
- 2016-08-26 CA CA3072922A patent/CA3072922A1/fr active Pending
- 2016-08-26 MA MA43458A patent/MA43458A1/fr unknown
- 2016-08-26 WO PCT/EP2016/070146 patent/WO2017036936A1/fr not_active Ceased
- 2016-08-26 MA MA43461A patent/MA43461B1/fr unknown
- 2016-08-26 TW TW107128393A patent/TWI699377B/zh not_active IP Right Cessation
- 2016-08-26 EA EA201890560A patent/EA201890560A1/ru unknown
- 2016-08-26 TW TW105127400A patent/TW201708246A/zh unknown
- 2016-08-26 MA MA43457A patent/MA43457A1/fr unknown
- 2016-08-26 MA MA042694A patent/MA42694A/fr unknown
- 2016-08-26 MA MA43459A patent/MA43459A1/fr unknown
- 2016-08-26 UA UAA201808797A patent/UA124577C2/uk unknown
- 2016-08-26 CA CA2996963A patent/CA2996963A1/fr active Pending
- 2016-08-26 CR CR20200492A patent/CR20200492A/es unknown
- 2016-08-26 SG SG10202001831SA patent/SG10202001831SA/en unknown
- 2016-08-26 TW TW108141492A patent/TWI722658B/zh not_active IP Right Cessation
- 2016-08-26 PE PE2018001375A patent/PE20181517A1/es unknown
-
2018
- 2018-05-17 US US15/982,293 patent/US10576132B2/en active Active
- 2018-05-17 US US15/982,500 patent/US10525114B2/en active Active
- 2018-10-18 AU AU2018250464A patent/AU2018250464B2/en not_active Ceased
-
2019
- 2019-11-04 US US16/673,619 patent/US10695411B2/en active Active
- 2019-11-04 US US16/673,608 patent/US10568950B1/en active Active
-
2020
- 2020-03-16 AU AU2020201896A patent/AU2020201896B2/en not_active Ceased
- 2020-05-29 US US16/887,765 patent/US10898557B2/en not_active Expired - Fee Related
- 2020-06-29 US US16/915,420 patent/US10898558B2/en not_active Expired - Fee Related
- 2020-09-10 US US17/017,358 patent/US11065316B2/en active Active
-
2021
- 2021-04-23 JP JP2021072989A patent/JP7506026B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43461A1 (fr) | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers | |
| MA43490A1 (fr) | Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers | |
| MA44101A (fr) | Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers | |
| MA43719B1 (fr) | Peptide à utiliser en immunothérapie contre le cancer du poumon non à petites cellules et le cancer du poumon à petites cellules | |
| MA43435B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003) | |
| MA46648B2 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers | |
| MA46022B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers | |
| MA42045A (fr) | Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers | |
| MA46508A1 (fr) | Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers | |
| MA43090A1 (fr) | Peptides, combinaisons de peptides et médicaments basés sur les cellules pour l'immunothérapie contre le cancer de la vessie urinaire et d'autres cancers | |
| MA42294B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
| MA42381A (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers | |
| MA41520B2 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
| MA44551A1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers | |
| MA41237B1 (fr) | Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers | |
| MA43330B1 (fr) | Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers | |
| MA47367B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
| MA43328A1 (fr) | Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers | |
| MA48487B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers | |
| MA46503A1 (fr) | Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers | |
| MA43596A1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l'œsophage et d'autres cancers | |
| MA41664A1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers |